JP2017523974A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523974A5
JP2017523974A5 JP2017505180A JP2017505180A JP2017523974A5 JP 2017523974 A5 JP2017523974 A5 JP 2017523974A5 JP 2017505180 A JP2017505180 A JP 2017505180A JP 2017505180 A JP2017505180 A JP 2017505180A JP 2017523974 A5 JP2017523974 A5 JP 2017523974A5
Authority
JP
Japan
Prior art keywords
composition according
injection
administered
months
methotrexate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523974A (ja
JP7097181B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/042951 external-priority patent/WO2016019165A1/en
Publication of JP2017523974A publication Critical patent/JP2017523974A/ja
Publication of JP2017523974A5 publication Critical patent/JP2017523974A5/ja
Application granted granted Critical
Publication of JP7097181B2 publication Critical patent/JP7097181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505180A 2014-07-30 2015-07-30 増殖性硝子体網膜症用メトトレキサート Active JP7097181B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462030778P 2014-07-30 2014-07-30
US62/030,778 2014-07-30
PCT/US2015/042951 WO2016019165A1 (en) 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020202357A Division JP2021059554A (ja) 2014-07-30 2020-12-07 増殖性硝子体網膜症用メトトレキサート

Publications (3)

Publication Number Publication Date
JP2017523974A JP2017523974A (ja) 2017-08-24
JP2017523974A5 true JP2017523974A5 (cg-RX-API-DMAC7.html) 2022-04-27
JP7097181B2 JP7097181B2 (ja) 2022-07-07

Family

ID=55218325

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017505180A Active JP7097181B2 (ja) 2014-07-30 2015-07-30 増殖性硝子体網膜症用メトトレキサート
JP2020202357A Pending JP2021059554A (ja) 2014-07-30 2020-12-07 増殖性硝子体網膜症用メトトレキサート
JP2023114963A Pending JP2023145527A (ja) 2014-07-30 2023-07-13 増殖性硝子体網膜症用メトトレキサート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020202357A Pending JP2021059554A (ja) 2014-07-30 2020-12-07 増殖性硝子体網膜症用メトトレキサート
JP2023114963A Pending JP2023145527A (ja) 2014-07-30 2023-07-13 増殖性硝子体網膜症用メトトレキサート

Country Status (6)

Country Link
US (4) US10098884B2 (cg-RX-API-DMAC7.html)
EP (3) EP3174540B9 (cg-RX-API-DMAC7.html)
JP (3) JP7097181B2 (cg-RX-API-DMAC7.html)
CA (2) CA2991921C (cg-RX-API-DMAC7.html)
ES (2) ES2969374T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016019165A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991921C (en) * 2014-07-30 2023-08-08 Massachusetts Eye And Ear Infirmary Methotrexate for proliferative vitreoretinopathy
WO2018027044A1 (en) * 2016-08-05 2018-02-08 Schepens Eye Research Institute Idelalisib for treating proliferative vitreoretinopathy and abnormal intraocular neovascularization
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
WO2021051003A1 (en) 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
CN115804665A (zh) * 2022-12-13 2023-03-17 南昌大学附属眼科医院 一种tpvr动物模型的建立方法
WO2024129979A1 (en) * 2022-12-14 2024-06-20 Aldeyra Therapeutics, Inc. Methotrexate treatment methods
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032734A1 (en) 2000-07-26 2002-03-14 Rhoads Geoffrey B. Collateral data combined with user characteristics to select web site
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
JP5001645B2 (ja) * 2004-04-02 2012-08-15 電気化学工業株式会社 ヒアルロン酸−メトトレキサート結合体
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
MX2007003968A (es) * 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20090081277A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US20110200662A1 (en) 2008-10-22 2011-08-18 Arnold Glazier Method For The Treatment Of Proliferative Disorders Of The Eye
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US20140105956A1 (en) * 2012-10-11 2014-04-17 Rupak BANERJEE Biodegradable polymer based microimplant for ocular drug delivery
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
CA2991921C (en) * 2014-07-30 2023-08-08 Massachusetts Eye And Ear Infirmary Methotrexate for proliferative vitreoretinopathy

Similar Documents

Publication Publication Date Title
Pérez-Torregrosa et al. Combined phacoemulsification and XEN45 surgery from a temporal approach and 2 incisions
Tyson et al. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery
Donnenfeld et al. Dexamethasone intracameral drug-delivery suspension for inflammation associated with cataract surgery: a randomized, placebo-controlled, phase III trial
Voskanyan et al. Prospective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: synergy trial
Hoeh et al. Early postoperative safety and surgical outcomes after implantation of a suprachoroidal micro-stent for the treatment of open-angle glaucoma concomitant with cataract surgery
Cao et al. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation
JP2021059554A5 (cg-RX-API-DMAC7.html)
Walters et al. Efficacy and safety of sustained release dexamethasone for the treatment of ocular pain and inflammation after cataract surgery: results from two phase 3 studies
Bratton et al. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis
Donnenfeld et al. Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study
Fadlallah et al. Safety and efficacy of femtosecond laser–assisted arcuate keratotomy to treat irregular astigmatism after penetrating keratoplasty
Delyfer et al. Adapted surgical procedure for Argus II retinal implantation: feasibility, safety, efficiency, and postoperative anatomic findings
Mylonas et al. Macular edema following cataract surgery in eyes with previous 23-gauge vitrectomy and peeling of the internal limiting membrane
Tai et al. Surgical outcomes of Baerveldt implants in pediatric glaucoma patients
Larochelle et al. Dexamethasone intravitreal implant in the treatment of uveitic macular edema in the perioperative cataract setting: a case series
Yildirim et al. Same-day intrastromal corneal ring segment and collagen cross-linking for ectasia after laser in situ keratomileusis: long-term results
Bhargava et al. Phacoemulsification versus manual small incision cataract surgery in patients with fuchs heterochromic iridocyclitis
JP7097181B2 (ja) 増殖性硝子体網膜症用メトトレキサート
Nagpal et al. Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy
Crawford et al. Endocapsular artificial iris implantation for iris defects: reducing symptoms, restoring visual function and improving cosmesis
Eshraghi et al. Scleral buckle removal: indications, timing, complications, and long-term outcomes
García et al. Management of the neovascular choroidal membrane secondary to ocular toxoplasmosis
Kilavuzoğlu et al. Treatment of mixed astigmatism: early clinical outcomes with WaveLight and Technolas excimer lasers
Abdelaziz et al. Collagen corneal cross-linking followed by Intac implantation in a case of post-PRK ectasia
Klufas et al. Surgical management of retinopathy of prematurity